Streetbeat News

Products Services

COIN

Dogwifhat (CRYPTO: WIF) surged 15%, challenging Floki Inu (CRYPTO: FLOKI) in valuation, with a notable increase in trading volumes and social activity. Investor Jake Gagain suggests Coinbase should list WIF, while MaxBecauseBTC, a financial market analyst, holds WIF as his largest meme coin investment, praising its performance. The upcoming Benzinga's Future of Digital Assets conference will discuss digital asset investments, highlighting the growing interest in meme coins like Dogwifhat.

Portfolio Pulse from Khyathi Dalal

March 25, 2024 | 8:36 pm

BTCUSD

Thomas Lee, co-founder of Fundstrat Global Advisors, accurately predicted Bitcoin's rise in 2018, suggesting it could reach $150,000 by capturing 1% of global assets. As of 2024, Bitcoin has surpassed $70,000, reflecting its increasing acceptance and role in financial portfolios. Lee's insights will be discussed at Benzinga's Future of Digital Assets conference, highlighting the growing market cap of cryptocurrencies and their appeal as an uncorrelated asset class for diversification.

Portfolio Pulse from Murtuza Merchant

March 25, 2024 | 8:26 pm

AVGO

HACK

NVDA

TRFK

Piper Sandler analyst Harsh V. Kumar highlighted Broadcom's (AVGO) advancements in custom accelerators and networking, positioning it for growth in generative AI for 2024. Nvidia (NVDA) also gained attention with its Blackwell chip and NIM software, aiming at AI startups and hyperscalers. Broadcom announced a third major U.S. hyperscaler customer for its XPU accelerators, promising significant power savings. Kumar projects Broadcom's 2024 revenue and EPS at $49.97 billion and $46.35, respectively. AVGO shares saw a minor decline, while exposure to Broadcom can also be gained through Pacer Data And Digital Revolution ETF (TRFK) and Amplify Cybersecurity ETF (HACK).

Portfolio Pulse from Anusuya Lahiri

March 25, 2024 | 8:18 pm

AMRX

Amneal Pharmaceuticals has received FDA approval for its Ciprofloxacin and Dexamethasone Otic Suspension, a product that references the branded Ciprodex. This approval represents the addition of another complex, high-value product to Amneal's portfolio.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:13 pm

SON

Sonoco announced a price increase of €60 per ton for uncoated recycled paperboard in Europe, with a £50 increase for the UK market. This adjustment is a response to market conditions.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:09 pm

STOK

Stoke Therapeutics announced promising Phase 1/2a end of study data for STK-001, showing significant reductions in convulsive seizure frequency in Dravet Syndrome patients. The data revealed 85% median reduction at 3 months and 74% at 6 months with 70mg doses. Open label extension studies showed durable seizure reductions and cognitive improvements over 12 months with 30mg and 45mg doses. STK-001 was well-tolerated, and the company plans to discuss registrational study design with regulatory agencies, aiming for initial doses of 70mg followed by 45mg. A webcast for analysts and investors is scheduled for 4:30 p.m. Eastern Time today.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:04 pm

ESPR

Esperion announced that data from the CLEAR Outcomes sub-groups will be presented in various formats, including poster presentations, a moderated session, and an Industry Expert Theatre at ACC.24.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:01 pm

VHAI

Vocodia has announced through a post on X that they are preparing for an exciting Q2 with a focus on innovation and growth. They hinted at upcoming announcements that will showcase their efforts to push boundaries and drive success.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 7:51 pm

VHAI

Vocodia has announced its focus on innovation and growth for Q2, teasing upcoming updates and expressing enthusiasm for future success.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 7:51 pm

MRK

Financial giants have shown a bullish stance on Merck & Co (NYSE:MRK) through options trading, with a notable lean towards calls over puts. Analysis of recent trades indicates a target price range of $120.0 to $135.0. The company, a major player in pharmaceuticals, has seen its stock price slightly increase to $123.86. Analyst ratings have varied, with a consensus target price of approximately $124.67, though opinions range from Overweight to Sell.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 7:46 pm